BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP

Imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but the primary and acquired imatinib resistance remains the big hurdle. Molecular mechanisms for CML resistance to tyrosine kinase inhibitors, beyond point mutations in BCR-ABL kinase domain, still need to be addre...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Lin, Ding, Ruxin, Qu, Xuan, Li, Yuanchun, Shen, Tong, Wang, Lei, Li, Ruikai, Zhang, Juan, Ru, Yi, Bu, Xin, Wang, Yang, Li, Min, Song, Wenqi, Shen, Liangliang, Zhang, Pengxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125982/
https://www.ncbi.nlm.nih.gov/pubmed/37095099
http://dx.doi.org/10.1038/s41419-023-05811-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125982/
https://www.ncbi.nlm.nih.gov/pubmed/37095099
http://dx.doi.org/10.1038/s41419-023-05811-2

Ejemplares similares